News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|January 2, 2025

New FDA-Approved Treatments for PPD

Author(s)Carmen Kosicek, MSN, PMHNP-BC, Deb York, MSN, PMHNP-BC, APRN, CCRA

Panelists discuss how the recent FDA-approved treatments for postpartum depression (PPD), including zuranolone and brexanolone , offer new options for rapid symptom relief and improve the management of severe PPD cases.

Episodes in this series

EP. 1 Overview of PPD and Current Management Practices

EP. 1 Overview of PPD and Current Management Practices

EP. 2 New FDA-Approved Treatments for PPD

EP. 2 New FDA-Approved Treatments for PPD

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 4 Diagnostic Tools for PPD

EP. 4 Diagnostic Tools for PPD

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

postpartum depression

EP. 10 Experts Share Top 7 Recommendations for Treating Postpartum Depression

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Experts featured in this series.

Multidisciplinary Approaches to Long-Term Narcolepsy Care

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 22nd 2026

Experts featured in this series.

Optimizing Narcolepsy Treatment Through Polypharmacy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 15th 2026

Experts featured in this series.

Assessing DEA Scheduling and Emerging Therapies in Narcolepsy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 15th 2026

Experts featured in this series.

Evaluating Pitolisant and Other Pharmacologic Treatment Options for Narcolepsy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 8th 2026

Experts featured in this series.

Narcolepsy Treatment Considerations in Pediatric Patients

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 8th 2026

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults